The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2017

Filed:

Feb. 26, 2015
Applicants:

Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);

Crucell Holland B.v., Leiden, NL;

Inventors:

Dan Barouch, Newton, MA (US);

Peter Abbink, Winthrop, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/00 (2006.01); A61K 39/21 (2006.01); A61K 39/235 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); C12N 2710/10052 (2013.01); C12N 2710/10143 (2013.01); C12N 2710/10171 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/16143 (2013.01); C12N 2710/16171 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16171 (2013.01);
Abstract

Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.


Find Patent Forward Citations

Loading…